SCHEMBL385791

SCHEMBL385791

[CH2]CC(CCCCC)SCC

nearest known ligand 0.36

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.36
GPR84 Q9NQS5 3/20 0.34
FFAR1 O14842 1/20 0.34
LMNA P02545 1/20 0.33
DNM1 Q05193 2/20 0.32
FDPS P14324 4/20 0.31
TSHR P16473 2/20 0.31
THRB P10828 1/20 0.30
SPHK1 Q9NYA1 1/20 0.30
CA1 P00915 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9842302 0.83
SCHEMBL7573974 0.83 FDPS (0.36) OPRM1GPR84FFAR1LMNADNM1
SCHEMBL387173 0.79 OPRM1 (0.37) OPRM1GPR84FFAR1LMNADNM1
SCHEMBL1454106 0.78 TSHR (0.41) TSHR
SCHEMBL10975409 0.78
SCHEMBL10529613 0.77 LMNA (0.38) OPRM1GPR84FFAR1LMNADNM1
SCHEMBL386456 0.77 LMNA (0.38) OPRM1GPR84FFAR1LMNADNM1
SCHEMBL1452404 0.75
SCHEMBL399939 0.74 DNM1 (0.30) DNM1
SCHEMBL19231160 0.73 DNM1 (0.36) LMNADNM1FDPSTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101650-B2 Method for treating a immunology-related disease DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-24 US disclosed
US-8067396-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2011-11-29 US disclosed
US-7910617-B2 Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound SANKYO COMPANY, LIMITED (JP) 2011-03-22 US disclosed
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-20090326038-A1 Method for treating a immunology-related disease SANKYO COMPANY, LIMITED (JP) 2009-12-31 US disclosed
US-7638551-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2009-12-29 US disclosed
EP-1471054-B1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE DAIICHI SANKYO CO LTD (JP) 2009-07-01 EP disclosed
US-20070191468-A1 Amino alcohol compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2007-08-16 US disclosed
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2007-06-21 US disclosed
US-20070105933-A1 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-05-10 US disclosed
EP-1733724-A1 AMINO ALCOHOL COMPOUND Sankyo Company, Limited (JP) 2006-12-20 EP disclosed
US-6964976-B2 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2005-11-15 US disclosed
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO COMPANY, LIMITED (JP) 2005-02-24 US disclosed
EP-1471054-A1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE Sankyo Company, Limited (JP) 2004-10-27 EP disclosed
US-20040132784-A1 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2004-07-08 US disclosed
US-6723745-B2 PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE IN WARM BLOODED ANIMAL SANKYO COMPANY, LIMITED (JP) 2004-04-20 US disclosed
US-20030236297-A1 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2003-12-25 US disclosed
EP-1300405-A1 AMINO ALCOHOL DERIVATIVES Sankyo Company, Limited (JP) 2003-04-09 EP disclosed
EP-1255989-A2 METHOD OF NON-TARGETED COMPLEX SAMPLE ANALYSIS Yol Bolsum Canada Inc. (CA) 2002-11-13 EP disclosed
WO-2001057518-A2 METHOD OF NON-TARGETED COMPLEX SAMPLE ANALYSIS YOL BOLSUM CANADA INC. (CA) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236297-A1 Amino alcohol derivatives CD4, ADH1C, ADH1A OPRM1 163/4885GPR84 1039/4885FFAR1 246/4885
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these PHOSPHO1, CD4, FCGRT OPRM1 575/4885GPR84 1483/4885FFAR1 78/4885
US-20040132784-A1 Amino alcohol derivatives CD4, ADH1C, ADH1A OPRM1 163/4885GPR84 1039/4885FFAR1 246/4885
US-20090326038-A1 Method for treating a immunology-related disease C3AR1, HRH3, HRH2 OPRM1 3794/4885GPR84 1496/4885FFAR1 549/4885
US-20070105933-A1 Amino alcohol compounds ADH1C, C9, SSB OPRM1 938/4885GPR84 1074/4885FFAR1 150/4885
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof HRH3, C3AR1, HRH4 OPRM1 2353/4885GPR84 681/4885FFAR1 63/4885
US-20070191468-A1 Amino alcohol compound ADH1A, ADH1C, BCAT1 OPRM1 204/4885GPR84 289/4885FFAR1 125/4885
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof PHOSPHO1, ADH1C, ADH1A OPRM1 753/4885GPR84 1221/4885FFAR1 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.